Cargando…

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells

Natural killer (NK) cells stand out as promising candidates for cellular immunotherapy due to their capacity to kill malignant cells. However, the therapeutic use of NK cells is often dependent on cell expansion and activation with considerable amounts of serum and exogenous cytokines. We aimed to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chrobok, Michael, Dahlberg, Carin I. M., Sayitoglu, Ece Canan, Beljanski, Vladimir, Nahi, Hareth, Gilljam, Mari, Stellan, Birgitta, Sutlu, Tolga, Duru, Adil Doganay, Alici, Evren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356567/ https://www.ncbi.nlm.nih.gov/pubmed/30634595 http://dx.doi.org/10.3390/cancers11010069

Ejemplares similares

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

Correction: Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells
por: Rossi, Fiorella, et al.
Publicado: (2021)

Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells
por: Rossi, Fiorella, et al.
Publicado: (2020)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
por: Sayitoglu, Ece Canan, et al.
Publicado: (2020)

Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity
por: Dahlberg, Carin I. M., et al.
Publicado: (2015)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer
por: Karahan, Zeynep Sena, et al.
Publicado: (2023)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

The Yin and Yang of Type 1 Regulatory T Cells: From Discovery to Clinical Application
por: Sayitoglu, Ece Canan, et al.
Publicado: (2021)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

Engineered NK Cells Against Cancer and Their Potential Applications Beyond
por: Karvouni, Maria, et al.
Publicado: (2022)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
por: Jakobsen Falk, Ingrid, et al.
Publicado: (2017)

Crystal structures of H-2D(b) in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity
por: Hafstrand, Ida, et al.
Publicado: (2017)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

Limited response of NK92 cells to Plasmodium falciparum-infected erythrocytes
por: de Carvalho, Elisandra Grangeiro, et al.
Publicado: (2011)

Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors
por: Yang, Chaopin, et al.
Publicado: (2019)

Efficient delivery of oncolytic enterovirus by carrier cell line NK-92
por: Podshivalova, Elizaveta Sergeevna, et al.
Publicado: (2021)

P1443: AUTOLOGOUS NK CELLS AS CONSOLIDATION AFTER FRONT-LINE STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A LONG-TERM FOLLOW-UP
por: Lund, J., et al.
Publicado: (2022)

Corrigendum: Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors
por: Yang, Chaopin, et al.
Publicado: (2019)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity
por: Shin, Hyun Young, et al.
Publicado: (2023)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data
por: Martins, José Paulo, et al.
Publicado: (2014)

Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS
por: Yoyen-Ermis, Digdem, et al.
Publicado: (2019)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Detection of Active Granzyme A in NK92 Cells with Fluorescent Activity-Based Probe
por: Kołt, Sonia, et al.
Publicado: (2020)

Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins
por: Huang, Rih-Sheng, et al.
Publicado: (2020)

Natural Killer Cell Line NK-92-Mediated Damage of Medically Important Fungi
por: Schmidt, Stanislaw, et al.
Publicado: (2021)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function
por: Abomaray, Fawaz, et al.
Publicado: (2021)

Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy
por: Navarrete-Galvan, Lydia, et al.
Publicado: (2022)

Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells
por: Rasul, Khder H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bnuu8agh719tjmsnls1spk9ph3